Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
- Foundation Purchases Caliper’s Staccato System to Enable High Throughput Research Processes -
“We would be unable to perform this type of large scale research without the Staccato workstation from Caliper,” said Dr.
The Functional Genomics Group at PMCC is funded by the Australian Cancer Research Foundation (ACRF) and provides Australian research institutes with access to large scale, high throughput gene knockdown technology that aids cancer research. By eliminating a gene’s ability to express, gene knockdown techniques may uncover ways to silence specific genes associated with cancer, leading to new forms of treatment. Researchers at PMCC are currently working with the Dharmacon entire human and mouse genome collections (~21,000 genes), attempting to knockdown each one. The Staccato enables the researcher to work through these gene sets in a rapid, systematic and reproducible way.
“The Peter MacCallum Cancer Centre’s decision to rely on the Staccato reinforces Caliper’s position as a leading provider of automation solutions for the life sciences industry,” said
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper and Staccato are registered trademarks of Caliper Life Sciences, Inc.
About Peter MacCallum Cancer Centre
In the midst of a worldwide effort, the Peter MacCallum Cancer Centre is in a powerful position to help in the war on cancer. It is one of a handful of comprehensive cancer centres outside
To be most effective, cancer research at Peter Mac has been structured in the form of multidisciplinary teams of laboratory scientists, clinician-researchers and allied health staff. Our spectrum of research ranges from laboratory-based studies into the fundamental mechanisms of cell growth, translational studies that seek more accurate cancer diagnosis, clinical trials with novel treatments, to research aimed at improving our supportive care of patients.
For more information about research at Peter Mac please visit www.petermac-research.org.
SOURCE Caliper Life Sciences, Inc.